Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.

Autor: Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA., Pinto D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA., Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA., De Marco A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Benigni F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Zatta F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Silacci-Fregni C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Bassi J; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA, USA., Addetia A; Department of Biochemistry, University of Washington, Seattle, WA, USA., Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA., Stewart C; Department of Biochemistry, University of Washington, Seattle, WA, USA., Giurdanella M; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Saliba C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Guarino B; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Schmid MA; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA., Logue JK; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA., Dang HV; Vir Biotechnology, San Francisco, CA, USA., Hauser K; Vir Biotechnology, San Francisco, CA, USA., di Iulio J; Vir Biotechnology, San Francisco, CA, USA., Rivera W; Vir Biotechnology, San Francisco, CA, USA., Schnell G; Vir Biotechnology, San Francisco, CA, USA., Rajesh A; Vir Biotechnology, San Francisco, CA, USA., Zhou J; Vir Biotechnology, San Francisco, CA, USA., Farhat N; Vir Biotechnology, San Francisco, CA, USA., Kaiser H; Vir Biotechnology, San Francisco, CA, USA., Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA., Noack J; Vir Biotechnology, San Francisco, CA, USA., Lempp FA; Vir Biotechnology, San Francisco, CA, USA., Janer J; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA., Abdelnabi R; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium., Maes P; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium., Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland., Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland., de Melo GD; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France., Kergoat L; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France., Bourhy H; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France., Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium., Soriaga L; Vir Biotechnology, San Francisco, CA, USA., Purcell LA; Vir Biotechnology, San Francisco, CA, USA., Snell G; Vir Biotechnology, San Francisco, CA, USA., Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA., Lanzavecchia A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA., Piccoli L; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Chu HY; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA., Pizzuto MS; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Corti D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Jazyk: angličtina
Zdroj: Science (New York, N.Y.) [Science] 2022 Nov 11; Vol. 378 (6620), pp. 619-627. Date of Electronic Publication: 2022 Oct 20.
DOI: 10.1126/science.adc9127
Abstrakt: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters elicit plasma-neutralizing antibodies against Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5, and that breakthrough infections, but not vaccination alone, induce neutralizing antibodies in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1, BA.2, and BA.4/5 receptor-binding domains, whereas Omicron primary infections elicit B cells of narrow specificity up to 6 months after infection. Although most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant-neutralizing antibody that is a strong candidate for clinical development.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje